Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial
Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial. // The Lancet Haematology. – URL: https://www.sciencedirect.com/science/article/pii/S2352302626001936?dgcid=rss_sd_all
Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial. The Lancet Haematology. https://www.sciencedirect.com/science/article/pii/S2352302626001936?dgcid=rss_sd_all
“Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial.” The Lancet Haematology.
@article{article68557,
title = {Clinical activity and safety of rilzabrutinib in patients with previously treated immune thrombocytopenia (LUNA3): results from the open-label period of a phase 3 trial},
journal = {The Lancet Haematology},
url = {https://www.sciencedirect.com/science/article/pii/S2352302626001936?dgcid=rss_sd_all}
}